Office of the Vice President for Research


Rallybio logo

Rallybio’s ambition is to identify and accelerate the development of transformative therapies for patients with severe and rare disorders.


Our Company is currently focused on building a portfolio of rare disease assets that meet our strategic filers:


Rallybio was founded and incorporated in January, 2018, and closed a $37M Series A financing in April, 2018. Investors include: 5AM Ventures, Cannan Partners, New Leaf Venture Partners, and Connecticut Innovations.